AN OBSERVATIONAL STUDY ON CARDIOVASCULAR INVOLVEMENT IN COVID RECOVERED PATIENTS

Aim of the study is to evaluate the prevalence and bring awareness ofcardiovascular complications in COVID-19 recovered patients. Study is conducted at single site, which is Srinivasa Heart Centre, Warangal, Telangana state in India for the duration of 4 months. The sample size is calculated 500 patients and the study is cohort, observational study. Patient consent has been taken before enrolment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Gender Discrimination Behavior Cardiac Event Cardiovascular Diseases Complication Prejudice Sexism Social Behavior Social Discrimination

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Srinivasa Heart Centre

Warangal, Telangana, 506001, India

About this study

The aim of the study is to evaluate the prevalence and bring awareness of cardiovascular complications in COVID-19 recovered patients.

Objectives of the study:

To study causes and risk factors of cardiac disorders associated with COVID-19
To identify different types of cardiac symptoms patients, present with
To study the impact of co-morbidities on COVID-19 recovered patients
To study treatment patterns and duration of therapy

Plan to study:

To select the patient based on inclusion and exclusion criteria
To collect the patient information from case sheets and by patient interaction
To identify different types of cardiac disorders related to COVID-19 or its treatment regimen
To study the management of COVID-19 complication and related cardiovascular disorders

Study Sites: Srinivasa Heart Centre, Warangal (T.S) Study Design: Observational cohort study Study Duration: 4 months

Subject Eligibility:

Inclusion Criteria

Patients who are willing to participate
Patients having previous COVID-19 treatment record
Prescriptions reported during the study period
The prescription which is legible and complete
Exclusion Criteria

Patients who are not willing to participate
The patient having no history of COVID-19 and available data

Source of the data:

Review of patient case sheet, prescription and lab reports
Personal interaction with patients and caregivers

Sample size: 500 Patients

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients who are willing to participate
Patients having previous COVID-19 treatment record
Prescriptions reported during the study period
The prescription which is legible and complete

Exclusion criteria

Patients who are not willing to participate
The patient having no history of COVID-19 and available data

Treatment and study plan

Difference in gender, response to disease, diagnostic test values

Behavioral

Gender difference: Prevalence of disease in male vs female Response to disease: Which group is more prone to cardiac involvement Diagnostic tests: Diagnostic confirmation of disease

Primary outcomes

ECG, Lipid profile, TMT, and 2D Echo

Time frame: September 2021 to February 2022

The following tests are performed to every individuals and relevant report are considered

Sponsors and collaborators

Lead sponsor

Kakatiya University

Other

Registry information

Important dates

Study start: 2021
Primary completion: 2022
Study completion: 2022
First posted: Feb 2, 2023
Registry last updated: Feb 3, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting